Sheila Weinmann to Breast Neoplasms
This is a "connection" page, showing publications Sheila Weinmann has written about Breast Neoplasms.
Connection Strength
1.989
-
Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors. Br J Cancer. 2026 Jan; 134(2):269-278.
Score: 0.133
-
Trends in Dose to the Contralateral Breast from Breast Cancer Radiotherapy in the United States. Radiat Res. 2025 Nov 01; 204(5):423-430.
Score: 0.133
-
Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates. Int J Radiat Oncol Biol Phys. 2025 Nov 15; 123(4):1090-1101.
Score: 0.130
-
Cellular senescence predicts breast cancer risk from benign breast disease biopsy images. Breast Cancer Res. 2025 Mar 11; 27(1):37.
Score: 0.127
-
Characteristics of women refusing follow-up for tests or symptoms suggestive of breast cancer. J Natl Cancer Inst Monogr. 2005; (35):33-8.
Score: 0.126
-
Implementation of systems strategies for breast and cervical cancer screening services in health maintenance organizations. Am J Manag Care. 2003 Nov; 9(11):745-55.
Score: 0.116
-
Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res. 2023 05 03; 25(1):50.
Score: 0.112
-
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022 11; 23(11):1451-1464.
Score: 0.108
-
A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):93-102.
Score: 0.107
-
Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer. JNCI Cancer Spectr. 2022 May 02; 6(3).
Score: 0.104
-
Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. Breast Cancer Res Treat. 2022 May; 193(1):203-216.
Score: 0.103
-
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nat Commun. 2021 11 03; 12(1):6341.
Score: 0.101
-
Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. Breast Cancer Res. 2021 01 30; 23(1):15.
Score: 0.096
-
Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition. Mol Carcinog. 2020 07; 59(7):701-712.
Score: 0.090
-
Response to Comment on "Bariatric Surgery is Associated With Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women". Ann Surg. 2020 02; 271(2):e19-e20.
Score: 0.089
-
RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery. BMC Med Genomics. 2019 12 19; 12(1):195.
Score: 0.089
-
A miRNA Expression Signature in Breast Tumor Tissue Is Associated with Risk of Distant Metastasis. Cancer Res. 2019 04 01; 79(7):1705-1713.
Score: 0.084
-
HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics. 2012; 15(1):1-10.
Score: 0.049
-
Late-stage breast cancer among women with recent negative screening mammography: do clinical encounters offer opportunity for earlier detection? J Natl Cancer Inst Monogr. 2005; (35):39-46.
Score: 0.031
-
Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst. 2004 Oct 20; 96(20):1518-27.
Score: 0.031
-
Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs. Genet Med. 2003 Nov-Dec; 5(6):444-50.
Score: 0.029